Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 211-212
DOI: 10.4103/0971-5851.123746
ORIGINAL ARTICLE

Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology

K G Srinivas
Department of Medical Oncology, Health-Care Global, Bangalore Institute of Oncology, Bengaluru, Karnataka, India
,
Shekar Patil
Department of Medical Oncology, Health-Care Global, Bangalore Institute of Oncology, Bengaluru, Karnataka, India
,
Shashidhara › Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Health-Care Global, Bangalore Institute of Oncology is a cancer care center, which provides comprehensive care for cancer patients. Here, we present data of 350 patients diagnosed as cases of chronic myeloid leukemia over a period of 10 years. In our patient population, there was male predominance and majority of patients lied between the age group of 40 and 50 years. 90% patients were initially started on 400 mg dose of imatinib. About 30% of patient population required dose excalation due to inadequate response while 10% required dose descalation due to myelosuppression. 60% of patients had complete response by 3 months and 52% of patients had major molecular response by 1 year.

Keywords

Bangalore - chronic myeloid leukemia - chronic phase


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Geary CG. The story of chronic myeloid leukaemia. Br J Haematol 2000;110:2-11.
  • 2 Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008;1:419-26.
  • 3 Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al.Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
  • 4 Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: What is the optimal strategy? Mayo Clin Proc 2009;84:161-9.
  • 5 Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-8.